Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Withdrawn × nilotinib × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 4 1 Phase 2 1 Phase 1/2 1

Status

Completed 9 Unknown 2 Terminated 2 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Metformin 3 Letrozole 3 Sperm Injections, Intracytoplasmic 2 Progesterone 2 Lidocaine 2 Indocyanine Green 2 Gentamicins 2 Estradiol 2 Clomiphene 2 Bevacizumab 2 tirbanibulin 1 technetium Tc 99m nanocolloid 1 suvorexant 1 pomalidomide 1 pembrolizumab 1 pasireotide 1 nilotinib 1 methylnaltrexone 1 ledipasvir 1 ixazomib 1 gadofosveset trisodium 1 exemestane 1 dolutegravir 1 ceftolozane, tazobactam drug combination 1 abemaciclib 1 Zoledronic Acid 1 Vortioxetine 1 Venlafaxine Hydrochloride 1 Trimethoprim, Sulfamethoxazole Drug Combination 1 Toremifene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01605981 2017-04-20

MACS1881

Novartis

Phase 4 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡